title: MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.
abstract: BACKGROUND
  Myeloid differentiation primary response 88 (MYD88) is a common adaptor protein that is responsible for signaling from several receptors; mutations in this gene may play a role in the pathogenesis of lymphoma.
  
  
  OBJECTIVE
  We aimed to determine the MYD88 L265P mutation frequency, the level of MYD88 expression, and their associations with clinicopathological parameters in mature B-cell non-Hodgkin lymphomas (NHLs).
  
  
  METHODS
  A total of 68 patients were included in the study. The presence of the MYD88 L265P mutation was analyzed by real-time polymerase chain reaction and direct sequencing. MYD88 protein expression was evaluated by immunohistochemistry (IHC) using two different scoring systems.
  
  
  RESULTS
  MYD88 L265P mutation was present in eight (18.6%) diffuse large B-cell lymphoma (DLBCL) patients. We also observed a significant association between the loss of MYD88 expression and advanced stage in both mature B-cell NHL and DLBCL according to the first IHC scoring systems (p=0.015 and p=0.024, respectively). An association was also seen between MYD88 overexpression and low clinical risk in both mature B-cell NHL and DLBCL according to the second IHC scoring system (p=0.027 and p=0.024, respectively).
  
  
  CONCLUSIONS
  The L265P mutation may be helpful for understanding the pathogenesis of immune-privileged site-associated DLBCLs. The presence of the mutation, together with its protein overexpression, could also be used as a prognostic marker in advanced stage DLBCLs.
authors.affiliation: 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Vildan
authors.initials: V
authors.lastname: Caner
authors.affiliation: 2 Tibbi Patoloji AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Nilay
authors.initials: N
authors.lastname: Sen Turk
authors.affiliation: 3 Tibbi Biyoloji AD, Pamukkale Universitesi , Denizli, Turkey .
authors.forename: Ikbal Cansu
authors.initials: IC
authors.lastname: Baris
authors.affiliation: 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Gokhan Ozan
authors.initials: GO
authors.lastname: Cetin
authors.affiliation: 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Emre
authors.initials: E
authors.lastname: Tepeli
authors.affiliation: 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Sibel
authors.initials: S
authors.lastname: Hacioglu
authors.affiliation: 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Ismail
authors.initials: I
authors.lastname: Sari
authors.affiliation: 3 Tibbi Biyoloji AD, Pamukkale Universitesi , Denizli, Turkey .
authors.forename: Sevil
authors.initials: S
authors.lastname: Zencir
authors.affiliation: 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Mehmet Hilmi
authors.initials: MH
authors.lastname: Dogu
authors.affiliation: 1 Tibbi Genetik AD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Gulseren
authors.initials: G
authors.lastname: Bagci
authors.affiliation: 4 Hematoloji BD, Pamukkale Universitesi Hastanesi , Denizli, Turkey .
authors.forename: Ali
authors.initials: A
authors.lastname: Keskin
mesh_terms: D000328:Adult; D005260:Female; D015870:Gene Expression; D056726:Genetic Association Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics* / Q000378:metabolism* / Q000473:pathology; D008297:Male; D009154:Mutation; D053594:Myeloid Differentiation Factor 88 / Q000096:biosynthesis* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D060888:Real-Time Polymerase Chain Reaction
chemical_list: C507779:MYD88 protein, human; D053594:Myeloid Differentiation Factor 88